Canaccord Genuity Adjusts Price Target on Merus to $67 From $54, Maintains Buy Rating
Merus Analyst Ratings
B of A Securities: Maintaining the Merus (MRUS.US) rating, adjusted from a buy rating to a buy rating, and the target price was adjusted from $61.00 to $80.00.
HC Wainwright & Co. Maintains Buy on Merus, Raises Price Target to $85
Analysts Offer Insights on Healthcare Companies: Corcept Therapeutics (CORT), Theravance Biopharma (TBPH) and Merus (MRUS)
Merus N.V.: H.C. Wainwright raised the target price from $65 to $85
Buy Rating Affirmed for Merus With Increased Price Objective Amid Promising Peto' Efficacy and Market Potential
Analysts Are Bullish on Top Healthcare Stocks: Merus (MRUS), Royalty Pharma (RPRX)
BMO Capital Adjusts Merus Price Target to $84 From $58, Maintains Outperform Rating
Stifel: Maintaining the Merus (MRUS.US) rating, adjusted from buy to buy rating, and the target price was adjusted from $65.00 to $90.00.
Merus Analyst Ratings
Stifel Maintains Buy on Merus, Raises Price Target to $90
Truist Financial Sticks to Its Buy Rating for Merus (MRUS)
Merus Rallies Ahead of Upcoming Presentations for Prospective Cancer Treatments, Price Target Boost at BoA Securities
Merus (MRUS) Receives a Buy From TD Cowen
Truist Financial Keeps Their Buy Rating on Merus (MRUS)
Merus Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Merus (MRUS) and Immunocore Holdings (IMCR)
Merus (MRUS) Initiated With a Buy at Truist Financial
Bank of America Securities Remains a Buy on Merus (MRUS)
No Data